Dr. Trevor Butcher is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati. He assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology.
Prior to joining the firm, Trevor earned his Ph.D. in organic chemistry from UC Berkeley in the lab of Professor John F. Hartwig and conducted his postdoctoral studies at the California Institute of Technology with Professor Brian M. Stoltz. Trevor has conducted research in the areas of synthetic methodology, transition metal catalysis, and natural product total synthesis resulting in twelve scientific publications, including one first-author publication in Nature.
Dr. Trevor Butcher is a patent agent in the San Diego office of Wilson Sonsini Goodrich & Rosati. He assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology.
Prior to joining the firm, Trevor earned his Ph.D. in organic chemistry from UC Berkeley in the lab of Professor John F. Hartwig and conducted his postdoctoral studies at the California Institute of Technology with Professor Brian M. Stoltz. Trevor has conducted research in the areas of synthetic methodology, transition metal catalysis, and natural product total synthesis resulting in twelve scientific publications, including one first-author publication in Nature.
- Postdoctoral Researcher, California Institute of Technology
NIH Postdoctoral Fellowship (96th percentile)
- Ph.D., Chemistry, University of California, Berkeley
NSF Predoctoral Fellow, UC Berkeley Fellow, Reaxys Ph.D. Prize Finalist, Merck Compound Challenge Finalist, 4.0 GPA
- B.S., Chemistry, West Virginia University
Barry M. Goldwater Scholar, Order of Augusta, 4.0 GPA
- U.S. Patent and Trademark Office
- Postdoctoral Researcher, California Institute of Technology
NIH Postdoctoral Fellowship (96th percentile)
- Ph.D., Chemistry, University of California, Berkeley
NSF Predoctoral Fellow, UC Berkeley Fellow, Reaxys Ph.D. Prize Finalist, Merck Compound Challenge Finalist, 4.0 GPA
- B.S., Chemistry, West Virginia University
Barry M. Goldwater Scholar, Order of Augusta, 4.0 GPA
- U.S. Patent and Trademark Office
Select Publications
- Co-author with W.M. Amberg and J.F. Hartwig, “Transition-Metal-Catalyzed Monofluoroalkylation: Strategies for the Synthesis of Alkyl Fluorides by C–C Bond Formation,” Angew. Chem., Int. Ed., 2021
- Co-author with J.L. Yang, W.M. Amberg, N.B. Watkins, N.D. Wilkinson, and J.F. Hartwig, “Desymmetrization of Difluoromethylene Groups by C–F Bond Activation,” Nature, 2020
- Co-author with J.L. Yang and J.F. Hartwig, “Copper-Catalyzed Defluorinative Borylation and Silylation of gem-Difluoroallyl Groups,” Org. Lett., 2020
- Co-author with S. Hanna, and J.F. Hartwig, “Contra-thermodynamic Olefin Isomerization by Chain-Walking Hydrofunctionalization and Formal Retro-hydrofunctionalization,” Org. Lett., 2019
- Co-author with A. Bunescu and J.F. Hartwig, “Traceless Silylation of β-C(sp3)–H Bonds of Alcohols via Perfluorinated Acetals,” J. Am. Chem. Soc., 2018
- Co-author with J.F. Hartwig, “Enantioselective Synthesis of Tertiary Allylic Fluorides by Iridium-Catalyzed Allylic Fluoroalkylation,” Angew. Chem., Int. Ed., 2018
- Co-author with E.J. McClain, T.G. Hamilton, T.M. Perrone, K.M. Kroner, G.C. Donohoe, N.G. Akhmedov, J.L. Petersen, and B.V. Popp, “Regioselective Copper-Catalyzed Boracarboxylation of Vinyl Arenes,” Org. Lett., 2016
- Co-author with Y. Xi, J. Zhang, and J.F. Hartwig, “Regioselective, Asymmetric Formal Hydroamination of Unactivated Internal Alkenes,” Angew. Chem., Int. Ed., 2016
- Co-author with H. Thakellapalli, B. Farajidizaji, N.G. Akhmedov, B.V. Popp, J.L. Petersen, and K.K. Wang, “Syntheses and Structures of Thiophene-Containing Cycloparaphenylenes and Related Carbon Nanohoops,” Org. Lett., 2015
Select Publications
- Co-author with W.M. Amberg and J.F. Hartwig, “Transition-Metal-Catalyzed Monofluoroalkylation: Strategies for the Synthesis of Alkyl Fluorides by C–C Bond Formation,” Angew. Chem., Int. Ed., 2021
- Co-author with J.L. Yang, W.M. Amberg, N.B. Watkins, N.D. Wilkinson, and J.F. Hartwig, “Desymmetrization of Difluoromethylene Groups by C–F Bond Activation,” Nature, 2020
- Co-author with J.L. Yang and J.F. Hartwig, “Copper-Catalyzed Defluorinative Borylation and Silylation of gem-Difluoroallyl Groups,” Org. Lett., 2020
- Co-author with S. Hanna, and J.F. Hartwig, “Contra-thermodynamic Olefin Isomerization by Chain-Walking Hydrofunctionalization and Formal Retro-hydrofunctionalization,” Org. Lett., 2019
- Co-author with A. Bunescu and J.F. Hartwig, “Traceless Silylation of β-C(sp3)–H Bonds of Alcohols via Perfluorinated Acetals,” J. Am. Chem. Soc., 2018
- Co-author with J.F. Hartwig, “Enantioselective Synthesis of Tertiary Allylic Fluorides by Iridium-Catalyzed Allylic Fluoroalkylation,” Angew. Chem., Int. Ed., 2018
- Co-author with E.J. McClain, T.G. Hamilton, T.M. Perrone, K.M. Kroner, G.C. Donohoe, N.G. Akhmedov, J.L. Petersen, and B.V. Popp, “Regioselective Copper-Catalyzed Boracarboxylation of Vinyl Arenes,” Org. Lett., 2016
- Co-author with Y. Xi, J. Zhang, and J.F. Hartwig, “Regioselective, Asymmetric Formal Hydroamination of Unactivated Internal Alkenes,” Angew. Chem., Int. Ed., 2016
- Co-author with H. Thakellapalli, B. Farajidizaji, N.G. Akhmedov, B.V. Popp, J.L. Petersen, and K.K. Wang, “Syntheses and Structures of Thiophene-Containing Cycloparaphenylenes and Related Carbon Nanohoops,” Org. Lett., 2015
Therapeutics and Drug Discovery
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Catalysis
- Chemical synthesis
- Chemistry
- Organic chemistry
- Organometallics
Therapeutics and Drug Discovery
- Small molecule synthesis
- Small molecules
Chemistry and Material Science
- Catalysis
- Chemical synthesis
- Chemistry
- Organic chemistry
- Organometallics
Verdiva is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. The company is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia.
- Privacy Policy
- Terms of Use
- Accessibility